{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T02:40:51Z","timestamp":1784256051705,"version":"3.55.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Urol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Historically, medical therapy of BPH has had its foundations in alpha-blockers in monotherapy or in combination with 5 alpha reductase inhibitors (5-ARIs); in particular, two important trials (COMBAT and MTOPS) have demonstrated the pivotal role of combination therapy instead of monotherapy and have individuated which patients are most likely to benefit from alpha-blockers, 5-ARIs, or their combination. However different side effects of these drugs, such erectile dysfunction, ejaculatory disorders, loss of libido, could affect the adherence to treatment. In fact, SeR-Se-Ly would work by blocking 5-alpha reductase and the binding between the dihydrotestosterone and the androgen receptor, antagonizing the a1-adrenergic receptor, and preventing cell proliferation and the production of COX-2 and 5-leukotrienes. Prior randomized controlled trials confirmed the use of alpha-blockers in conjunction with Lipidic Extract (LE) of Serenoa Repens (SeR), specifically compounds containing both Selenium (Se) and Lycopene (Ly). Based on these premises, the aim of this Italian multicenter case-control prospective non-randomized study is to compare the therapy with SeR-Se-Ly alone versus Dutasteride alone against BPH, in order to research a good therapeutic alternative with limited side effects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>From April 2021 to April 2022, 269 consecutive patients from 21 Italian centers were enrolled in this case-control study. The inclusion criteria were: age between 55 and 80 years old, digital rectal examination negative for prostate nodules, PSA&amp;lt;&amp;lt;4 ng\/ml, IPSS&amp;lt;&amp;gt;12, prostate volume &amp;gt;40 cc (assessed by ultrasound), Qmax &amp;lt;&amp;lt;15 ml\/sec. Patients with prostate cancer, prior bladder cancer, diabetes mellitus, neurogenic disorders, severe liver disease, history of orthostatic hypotension or syncope, recent a-blocker treatment (within 1 month) or phytotherapy, including saw palmetto extract (within 3 months), prior medical therapy with 5-ARI or surgical treatment for LUTS\/BPH, patients with catheter or QoL, Qmax measured at an episode of acute urine retention within the last 4 weeks, and patients with any ejaculatory disorders were excluded. During treatment period, patients received SeR-Se-Ly for one year (Group A), or Dutasteride 0.5mg for one year (Group B). The main outcome measures included International Prostatic Symptoms Score (IPSS) and IPSS quality-of -life (QoL), International Index of Erectile Function (IIEF-5), Qmax measured at uroflowmetry and the Male Sexual Health Questionnaire (MSHQ).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We have observed increasing of Qmax of 2 points in group A and 2,5 points group B; IPSS has been reduced of 4 points in group A and 4,5 points in group B; IIEF-5 didn\u2019t change in group A and it has been reduced in group B by -1; regarding the MSHQ, only the item MSHQ-Satisfaction has changed in group A: -1, in group B MSHQ was reduced by -2 points in ED, by -5 points in EJ, by -2,5 points in Satisfaction, by -0,5 points in Intercourse, by -3,2 points in Desire.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>SeR-Se-Ly could be a valid alternative to dutasteride, providing comparable effects on symptoms related to LUTS\/BPH and avoiding sexual dysfunctions. SeR-Se-Ly should not be substituted for dutasteride in those patients for whom prostate volume reduction is desired.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fruro.2025.1565240","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T05:25:20Z","timestamp":1745558720000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparison of Serenoa repens, lycopene, and selenium versus dutasteride for the treatment of LUTS\/BPH: an Italian multicenter case-control prospective study (COMP study)"],"prefix":"10.3389","volume":"5","author":[{"given":"Giuseppe","family":"Morgia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Lo Giudice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiano","family":"Cimino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Reale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Largan\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enza","family":"La Manna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Madonia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Tedde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Santaniello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Vespasiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Zaganelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Arnone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Cruciano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Carrino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Persico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Terrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafaela","family":"Malinaric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Minervini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Carini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio Ivan","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.842008","article-title":"Immune cell proinflammatory microenvironment and androgen-related metabolic regulation during benign prostatic hyperplasia in aging","volume":"13","author":"Cao","year":"2022","journal-title":"Front Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/bju.12802","article-title":"Baseline characteristics predict risk of progression and response to combined medical therapy for benign prostatic hyperplasia (BPH)","volume":"115","author":"Kozminski","year":"2015","journal-title":"BJU Int"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2011.10129.x","article-title":"The effects of dutasteride or tamsulosin alone and in combination on storage and voiding symptoms in men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH): 4-year data from the Combination of Avodart and Tamsulosin (CombAT) study","volume":"107","author":"Montorsi","year":"2011","journal-title":"BJU Int"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.5152\/tud.2021.21128","article-title":"Role of Rezum in the treatment of benign prostate hyperplasia: A review of the literature","volume":"47","author":"Cocci","year":"2021","journal-title":"T\u00fcrk \u00dcroloji Dergisi\/Turkish J Urol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/pros.22866","article-title":"Serenoa repens, lycopene and selenium versus tamsulosin for the treatment of LUTS\/BPH. An Italian multicenter double-blinded randomized study between single or combination therapy (PROCOMB trial)","volume":"74","author":"Morgia","year":"2014","journal-title":"Prostate"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2011.05.049","article-title":"The combination of serenoa repens, selenium and lycopene is more effective than serenoa repens alone to prevent hormone dependent prostatic growth","volume":"186","author":"Altavilla","year":"2011","journal-title":"J Urol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/00005392-199609000-00050","article-title":"The correlation between bladder outlet obstruction and lower urinary tract symptoms as measured by the international prostate symptom score","volume":"156","author":"el Din","year":"1996","journal-title":"J Urol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijir.3900859","article-title":"The use of the simplified International Index of Erectile Function (IIEF-5) as a diagnostic tool to study the prevalence of erectile dysfunction","volume":"14","author":"Rhoden","year":"2002","journal-title":"Int J Impot Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2025.02.026","article-title":"European association of urology guidelines on male sexual and reproductive health: 2025 Update on male infertility","author":"Minhas","year":"2025","journal-title":"Eur Urol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1590\/S1677-5538.IBJU.2013.02.10","article-title":"Effects of Serenoa Repens, Selenium and Lycopene (Profluss\u00ae) on chronic inflammation associated with Benign Prostatic Hyperplasia: results of \u201cFLOG\u201d (Flogosis and Profluss in Prostatic and Genital Disease), a multicentre Italian study","volume":"39","author":"Morgia","year":"2013","journal-title":"Int Braz J Urol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2004.04.056","article-title":"Male Sexual Health Questionnaire (MSHQ): scale development and psychometric validation","volume":"64","author":"Rosen","year":"2004","journal-title":"Urology"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.4081\/aiua.2019.3.139","article-title":"Nutraceutical treatment and prevention of benign prostatic hyperplasia and prostate cancer","volume":"91","author":"Cicero","year":"2019","journal-title":"Archivio Italiano Di Urol e Androl"},{"key":"B13","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1080\/13685538.2017.1365834","article-title":"Association between dietary phytoestrogens intakes and prostate cancer risk in Sicily","volume":"21","author":"Russo","year":"2018","journal-title":"Aging Male"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctim.2018.05.002","article-title":"Association between dietary flavonoids intake and prostate cancer risk: A case-control study in Sicily","volume":"39","author":"Reale","year":"2018","journal-title":"Complement Ther Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1590\/S1677-5538.IBJU.2015.0095","article-title":"Metabolic syndrome and prostatic disease: potentially role of polyphenols in preventive strategies. A review","volume":"42","author":"Castelli","year":"2016","journal-title":"Int Braz J Urol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/pros.24185","article-title":"SRSF-1 and microvessel density immunohistochemical analysis by semi-automated tissue microarray in prostate cancer patients with diabetes (DIAMOND study)","volume":"81","author":"Broggi","year":"2021","journal-title":"Prostate"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030948","article-title":"Is there a role of Warburg effect in prostate cancer aggressiveness? Analysis of expression of enzymes of lipidic metabolism by immunohistochemistry in prostate cancer patients (DIAMOND study)","volume":"15","author":"Russo","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.trsl.2021.07.002","article-title":"Insulin signaling, androgen receptor and PSMA immunohistochemical analysis by semi-automated tissue microarray in prostate cancer with diabetes (DIAMOND study)","volume":"238","author":"Broggi","year":"2021","journal-title":"Trans Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/app12052268","article-title":"The clinical role of SRSF1 expression in cancer: A review of the current literature","volume":"12","author":"Lo Giudice","year":"2022","journal-title":"Appl Sci"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14174212","article-title":"Genomic landscape alterations in primary tumor and matched lymph node metastasis in hormone-na\u00efve prostate cancer patients","volume":"14","author":"Russo","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-022-00600-y","article-title":"Oncological outcomes of cribriform histology pattern in prostate cancer patients: a systematic review and meta-analysis","volume":"26","author":"Russo","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1159\/000302716","article-title":"Treatment of Chronic Prostatitis\/Chronic Pelvic Pain Syndrome Category IIIA with Serenoa repens plus Selenium and Lycopene (Profluss\u00ae) versus S. repens Alone: An Italian Randomized Multicenter-Controlled Study","volume":"84","author":"Morgia","year":"2010","journal-title":"Urol Int"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1177\/1756287211418725","article-title":"Serenoa repens extract in the treatment of benign prostatic hyperplasia","volume":"3","author":"Geavlete","year":"2011","journal-title":"Ther Adv Urol"},{"key":"B24","article-title":"Serenoa repens for benign prostatic hyperplasia","volume-title":"Cochrane Database of Systematic Reviews","author":"Tacklind","year":"2009"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/ptr.4696","article-title":"Improving BPH symptoms and sexual dysfunctions with a saw palmetto preparation? Results from a pilot trial","volume":"27","author":"Suter","year":"2013","journal-title":"Phytother Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/antiox11020251","article-title":"The role of selenium in pathologies: an updated review","volume":"11","author":"Barchielli","year":"2022","journal-title":"Antioxidants"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-0191","article-title":"Selenium and the thyroid: A close-knit connection","volume":"95","author":"Duntas","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3945\/ajcn.111.033373","article-title":"Selenium and prostate cancer: systematic review and meta-analysis","volume":"96","author":"Hurst","year":"2012","journal-title":"Am J Clin Nutr"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1089\/jmf.2012.2682","article-title":"Effect of lycopene supplementation on oxidative stress: an exploratory systematic review and meta-analysis of randomized controlled trials","volume":"16","author":"Chen","year":"2013","journal-title":"J Med Food"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e1260","DOI":"10.1097\/MD.0000000000001260","article-title":"Lycopene and risk of prostate cancer","volume":"94","author":"Chen","year":"2015","journal-title":"Medicine"}],"container-title":["Frontiers in Urology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fruro.2025.1565240\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T05:25:21Z","timestamp":1745558721000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fruro.2025.1565240\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,25]]},"references-count":30,"alternative-id":["10.3389\/fruro.2025.1565240"],"URL":"https:\/\/doi.org\/10.3389\/fruro.2025.1565240","relation":{},"ISSN":["2673-9828"],"issn-type":[{"value":"2673-9828","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,25]]},"article-number":"1565240"}}